Drug Database
Back to search

France· FR:67629484

QINLOCK 50 mg, comprimé

A ripretinib product containing riprétinib, registered in France by DECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L01EX19

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedQINLOCK 50 mg, compriméATCL01EX19REGISTER NO.FR:67629484PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about riprétinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ripretinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EX19 (ripretinib), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose
Search ripretinib products by name

Ripretinib · ATC L01EX19

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ripretinib costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.72 in France to $744.16 in Switzerland — a ×1040 gap.

  • France: $0.72 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ripretinib · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

  • CH Switzerland$744.16
  • FR France$0.72
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
RIPRÉTINIB
Manufacturer
DECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
Country
France (FR)
ATC code
L01EX19
ATC class
Ripretinib
Defined daily dose
0.15 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930243640
    1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 90 comprimé(s)
    EUR 18.86

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

133 interactions on record for ripretinib.

Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ripretinib against other medicinesHow interaction checks work

Ripretinib · interactions on record

133 records

  • 12 severe
  • 121 moderate

Most severe, free to view

  • KetoconazoleH02CA03severe
  • ClarithromycinJ01FA09severe
  • KetoconazoleJ02AB02severe
  • Darunavir and cobicistatJ05AR14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ripretinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ripretinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Qinlock
  • Liechtenstein · Qinlock
  • Norway · Qinlock

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c06ef63f-e18b-4e56-b9ec-878402afab9d
GET /v1/drugs/c06ef63f-e18b-4e56-b9ec-878402afab9d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "67629484",
  "date_amm": "2021-11-18",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/21/1569",
  "substance": "RIPRÉTINIB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about ripretinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console